Interdisciplinary

Unique Environment

Precision Oncology

Molecular Mechanisms

Innovation

Translation and Reverse Translation

Spirit of collaboration

Exceptional Career Opportunities

Interdisciplinary Education

Team Culture

Bottom-up Ideas

Shared Cutting Edge Resources

Research at FCI

Clinical Translation Programs
Strategic Core of FCI

Multidisciplinary teams consisting of clinicians, tumor biologists, biochemists, chemists and bioinformaticians work together in these interdisciplinary research projects. The teams rely on the technology platforms provided by the five research areas.

Read more

P1
Proteomics & Functional Genomics

The goal of Technology Platform 1 is to find individual parameters that can improve the diagnosis of tumors or better predict the response to therapy. For example, the composition of all proteins in a cell can be qualitatively and quantitatively analyzed by means of mass spectrometry. The measured profile (“proteome”) contains unique information – similar to a fingerprint – and by comparing tumor cells with healthy cells of the same patient, new prognostic and diagnostic criteria can be identified.

Read more

P2
Immuno-Oncology

Technology platform 2 Immuno-Oncology uses the innovative cell type-specific gene transfer technologies available at FCI to develop new immunotherapeutic concepts. These include the genetic modification of T lymphocytes or natural killer cells (NKs) with chimeric antigen receptors (CARs) as well as the precise transfer of immunomodulatory agents into tumor tissue. This is complemented by the Immunomonitoring Platform.

Read more

P3
Tumor Models

The aim of Technology Platform 3 Tumor Models is to develop new tumor models that can be used to better predict the clinical success of a compound identified in basic research in patients. This platform represents the essential link for the transfer of new therapeutic strategies into the clinic.

Read more

P4
Drug Development

The goal of the Technology Platform 4 is to develop new therapeutic approaches and to advance them to the development of new drugs. The extensive chemical, pharmaceutical and structural biology expertise at Goethe University in Frankfurt makes it possible to develop and optimize new drug candidates against validated target structures; innovative biologicals and cell therapeutics are developed at Georg-Speyer-Haus and the Paul-Ehrlich-Institut.

Read more

P5
Clinical Translation & Biobank

The integration of clinical trials into the FCI is essential as an endpoint for drug development and a starting point for the investigation of response and resistance mechanisms. The goal is to initiate such studies in close collaboration with the University Center for Tumor Diseases (UCT). The UCT Frankfurt has continuously worked on the expansion of a comprehensive clinical research unit, which will be fully available to the FCI. This ensures the practical implementation of early translational studies at the FCI site.

Read more

Discovery & Development

The primary objective of this program is to address excellent hypotheses on basic biological mechanisms of tumorigenesis, progression, diagnosis, and therapy.

Read more

Events

Targeting Lineage Plasticity in Prostate Cancer

22-04-2024
11:00 - 12:00
Wouter Richard Karthaus, EPFL School of Life Sciences, Switzerland
Henner Farin
Georg-Speyer-Haus, Lecture hall, ground floor
Save Event

Tumor-associated neutrophils in non-small cell lung cancer

29-05-2024 - 29-05-2024
14:30 - 15:30
Etienne Meylan, Lung Cancer & Immuno-Oncology Laboratory, Université Libre de Bruxelles
Florian Greten
Georg-Speyer-Haus, Lecture hall, ground floor
Save Event

3rd Frankfurt Cancer Conference 2024 „Targeting the tumor-host interface“.

28-08-2024 - 30-08-2024
Various
Campus Westend, Auditorium Complex, Goethe University, Frankfurt am Main, Germany
Save Event

5th Rhein-Main Cancer Retreat

07-11-2024 - 08-11-2024
9:00 - 18:00
Various,
DKTK / LOEWE-FCI / MSNZ
Collegium Glashütten
Save Event

Symposium – tba

03-12-2024 - 04-12-2024
9:00 - 17:00
Various, various
Zuzana Tatarova
Save Event

Press Releases

2024-03-22

New Research Results – Safety of Short-Term Cultivated CAR T Cells in Cancer Immunotherapy

To the article

2024-02-01

The German Science and Humanities Council (Wissenschaftsrat) attests the Georg-Speyer-Haus “Impressive contributions to tumor research”

To the article

2024-01-02

Katharina Imkeller appointed Professor for Translational Neurooncology and Quantitative Immunology at LOEWE-Zentrum Frankfurt Cancer Institute

To the article